Hospira acquires EndoTool business from MD Scientific

As part of the agreement, Hospira has acquired additional assets related to the EndoTool business, including the MD Scientific headquarters in Charlotte, North Carolina and the employees supporting the product. Financial details of the agreement were not disclosed.

The EndoTool glucose management system, a software system cleared by the FDA, helps establish and maintain glycemic control in acute, critical care and operating room settings by calculating the dose of intravenous (IV) insulin needed to effectively control blood glucose levels.

EndoTool actively models and adapts to individual patient responses to I.V. insulin to help manage current and predict future dosage levels. It is said to be the only software that uses five separate data points – based on the patient’s most recent blood glucose readings – to provide personalized, safe and effective glycemic control.

Chris Kolber, president of global devices at Hospira, said: “This acquisition represents an important extension of Hospira’s commitment to improved outcomes, patient safety and enhanced clinician efficiency. With EndoTool in the Hospira portfolio, we are underscoring our commitment to technological leadership in the important area of clinical-decision support systems.”